HC Wainwright Issues Optimistic Estimate for ACRV Earnings

Acrivon Therapeutics, Inc. (NASDAQ:ACRV) – Equities researchers at HC Wainwright lifted their Q3 2025 EPS estimates for shares of Acrivon Therapeutics in a research note issued on Thursday, May 15th. HC Wainwright analyst E. Bodnar now forecasts that the company will earn ($0.52) per share for the quarter, up from their prior forecast of ($0.53). HC Wainwright has a “Buy” rating and a $19.00 price target on the stock. The consensus estimate for Acrivon Therapeutics’ current full-year earnings is ($2.49) per share. HC Wainwright also issued estimates for Acrivon Therapeutics’ Q4 2025 earnings at ($0.58) EPS, FY2025 earnings at ($2.12) EPS, FY2026 earnings at ($2.63) EPS, FY2027 earnings at ($2.52) EPS, FY2028 earnings at ($1.93) EPS and FY2029 earnings at ($1.24) EPS.

Other research analysts have also issued reports about the company. KeyCorp started coverage on Acrivon Therapeutics in a report on Friday, January 31st. They set an “overweight” rating on the stock. Jones Trading reissued a “hold” rating on shares of Acrivon Therapeutics in a research note on Friday. Oppenheimer reduced their price objective on shares of Acrivon Therapeutics from $10.00 to $9.00 and set an “outperform” rating for the company in a research note on Thursday, May 15th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Acrivon Therapeutics in a report on Wednesday, March 26th. Finally, Piper Sandler assumed coverage on shares of Acrivon Therapeutics in a research report on Monday, May 5th. They issued an “overweight” rating and a $6.00 target price on the stock. One research analyst has rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $17.71.

Acrivon Therapeutics Price Performance

Shares of NASDAQ:ACRV opened at $1.18 on Monday. The stock has a market cap of $37.00 million, a price-to-earnings ratio of -0.44 and a beta of 1.88. Acrivon Therapeutics has a 12 month low of $1.09 and a 12 month high of $10.16. The stock’s 50 day moving average price is $2.28 and its 200 day moving average price is $4.88.

Acrivon Therapeutics (NASDAQ:ACRV) last issued its quarterly earnings results on Tuesday, May 13th. The company reported ($0.51) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.06.

Insider Activity

In other news, major shareholder Perceptive Advisors Llc sold 215,283 shares of the stock in a transaction on Monday, April 28th. The shares were sold at an average price of $1.56, for a total transaction of $335,841.48. Following the transaction, the insider now owns 4,090,906 shares in the company, valued at $6,381,813.36. This represents a 5.00% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders sold a total of 1,707,833 shares of company stock worth $3,009,858 in the last three months. 11.90% of the stock is owned by insiders.

Institutional Investors Weigh In On Acrivon Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Wealthedge Investment Advisors LLC increased its position in Acrivon Therapeutics by 420.1% during the first quarter. Wealthedge Investment Advisors LLC now owns 56,467 shares of the company’s stock worth $115,000 after buying an additional 45,610 shares during the last quarter. Nuveen LLC bought a new stake in shares of Acrivon Therapeutics during the 1st quarter worth about $27,000. Invesco Ltd. acquired a new position in shares of Acrivon Therapeutics during the 1st quarter valued at about $72,000. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in shares of Acrivon Therapeutics by 29.7% during the 4th quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 102,784 shares of the company’s stock valued at $619,000 after acquiring an additional 23,535 shares during the last quarter. Finally, Corton Capital Inc. bought a new position in shares of Acrivon Therapeutics in the 4th quarter valued at approximately $73,000. Institutional investors and hedge funds own 71.62% of the company’s stock.

About Acrivon Therapeutics

Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.